TABLE 1.

Baseline characteristics and virological response rates of the patients

Patient	Age (yr)	Sexa	ALT level (IU/liter)	HAIb		Stageb		Previous IFN treatment?	ETR?c	EFUR?c
				Before	After	Before	After
1	19	F	102	6		1		No	No	No
2	38	M	119	5		2		No	No	No
3	29	M	75	12	15	3	3	No	No	No
4	45	M	246	4		2		Yes	Yes	No
5	40	M	62	4	4	1	1	No	Yes	No
6	34	M	183	9	5	1	1	Yes	Yes	Yes
7	35	F	67	8		3		No	No	No
8	38	M	92	13		1		No	No	No
9	19	M	63	4	4	1	1	Yes	No	No
10	23	F	115	17		3		Yes	No	No
11	23	M	52	7		1		No	Yes	No
12	44	M	103	4	9	1	3	No	No	No
13	49	M	103	12		4		Yes	No	No
14	63	M	152	12	9	4	4	Yes	Yes	Yes
15	40	F	53	13		4		No	Yes	Yes
16	20	M	67	4	5	1	2	No	No	No
17	51	M	60	12		4		Yes	Yes	No
18	57	M	80	8	4	3	2	Yes	Yes	Yes
19	34	M	61	6	12	3	3	No	No	No

^aF, female; M, male.

^bHAI and stage scores were determined before and after treatment.

^cETR, end-of-treatment virological response; EFUR, end-of-follow-up virological response.